You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ)盤中現拉昇 溢價12.76倍收購金賽藥業29.5%股權
格隆匯 11-12 11:09
格隆匯11月12日丨今年以來,一直在籌謀收購公司控股子公司金賽藥業股權事宜的長春高新(000661.SZ)在11月8日創出歷史新高價486.7元后,今日盤中出現一波快速拉昇,截至目前報472.08元,漲1.71%,暫成交5.66億元,最新總市值805億元。該股年初至今累漲170%。

公司昨日發佈最新重組報告書稱,溢價12.76倍收購金賽藥業29.5%股權。作為國內生產重組人生長激素的龍頭企業,金賽藥業是長春高新最核心的子公司。
歷年數據顯示,金賽藥業的營收從2012年的7.25億元增至2018年的31.96億元,淨利潤亦從2.59億元增至2018年的11.32億元;2019年上半年,金賽藥業實現營收9.93億元,淨利潤為8.23億元;2017年-2019年上半年,其主營業務毛利率分別高達92.02%、92.95%和93.37%。
截至2019年6月末,金賽藥業還有15項在研產品,其中絕大部分是治療用生物製品,除了以往關注的生長領域疾病外,還涉及到腫瘤相關的單抗研發。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account